Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon's aspheric IOL (intraocular lens)

This article was originally published in Clinica

Executive Summary

The US FDA has given Alcon Laboratories approval to market its AcrySof ReSTOR apodised diffractive aspheric intraocular lens (IOL) for the visual correction of aphakia following cataract surgery in adults with and without presbyopia. The product is the only FDA-approved presbyopia-correcting IOL that incorporates aspheric optics into its design, claimed the firm, a subsidiary of Fort Worth, Texas-based Alcon. A phased commercial launch of the lens will begin after necessary consignment quantities are established, with full distribution expected by the middle of the year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel